Software/Hardware Engineer in MedTech Startup

By | RESPINOR general news | No Comments

RESPINOR is a Norwegian medical device company founded in 2015 and is twice ranked number one among 237 companies in the EU commissions Horizon 2020 program. We are developing a novel non-invasive medical device, using ultrasound for continuous monitoring of the diaphragm, the main breathing muscle. We aim at providing an objective measure of breathing, addressing a global market with a cutting-edge medical technology. Currently the company is conducting research and development and has initiated clinical feasibility studies in Europe for the first indication mechanical ventilation (MV) and will expand into other markets globally. Our technology has a broad range of potential benefits and represents an enabling technology platform for applications in critical care and other areas of respiratory medicine. See more at  www.respinor.com

Software/Hardware Engineer:

Respinor is seeking a ​SW/HW Engineer to join our team of dedicated professionals. You will be a key member of the Technical Team contributing to specification, development, test, documentation and support activities of the company’s products and the clinical testing and deployment.

Responsibilities:

  • Participate in SW development, including defining SW requirements, code development, validation, signal processing, unit and integration testing
  • Participate in HW development
  • Contribute to successful integration of SW with electromechanical and consumable components
  • Coordinate with external development partners as needed
  • Troubleshooting and problem-solving related to SW and HW aspects of the design and interfaces with other design constituents
  • Some travel may be required to support clinical testing

Key competencies:

  • Bachelor’s in computer science or computer engineering
  • Programming language experience (C++, Python, C)
  • Domain knowledge; Signal processing
  • Excellent written and verbal English skills

In addition, we are looking for experience with:

  • Linux OS
  • Microcontrollers, embedded Linux
  • Domain knowledge; Analog HW, Realtime, Safety, Security, documentation, medical instruments and development thereof

Who are you?

  • You are driven by new challenges and thrives in a dynamic work environment
  • Systematic and self-going
  • Strong analytical problem-solving skills
  • Solution-minded team player

The position reports to Lead Engineer.

We can offer a vibrant and creative working environment in the Norway Health Tech cluster situated in Oslo Science Park (Forskningsparken).

For more information about the application process, please contact George Refseth (Lead Engineer) +47 90482060  or Trude Tingvoll  (CEO)+47 453 313

Please send your motivational letter and CV in PDF format to mail@respinor.com

First patient enrolled in RESPINOR’s mechanical ventilation WEAN-US study at Hospitalier Pitié-Salpêtrière in Paris, France.

By | RESPINOR general news | No Comments

The study Principal Investigator, Prof. Alexandre Demoule, with the study equipment including RESPINOR DXT and pressure measuring hardware.

Study title: Improvement of weaning from mechanical ventilation by continuous ultrasound monitoring of diaphragm excursion: the WEAN-US Study.

The objective of the study is to evaluate the feasibility of “RESPINOR DXT” for continuous monitoring of diaphragmatic excursion in patients undergoing mechanical ventilation in intensive care, to validate these measurements by comparing them with standard ultrasound data as well as transdiaphragmatic pressure measured simultaneously and to establish a link between diaphragmatic excursion and the outcome of weaning from mechanical ventilation.

Our hypothesis is that the continuous measurement of the right hemi-diaphragmatic excursion by the RESPINOR DXT device is feasible, reliable and that there is a statistical link between the amplitude of this excursion and the success of withdrawal from mechanical ventilation.

RESPINOR AS: A Norwegian medical device company founded in 2015 based on IP, prototypes and clinical development at the University of Oslo and NeoRad AS. RESPINOR is developing an objective measure of breathing for critically ill patients within intensive care. RESPINOR DXT (Diaphragm Excursion Technology) is non-invasive, easy to use and provides precise, real-time continuous monitoring of the diaphragm function, our main breathing muscle. Monitoring the up-and-down movement of the liver, RESPINOR DXT measures diaphragm excursion using the liver as a proxy for the motion of the diaphragm. The monitoring of the diaphragm may provide useful information to guide clinical decision making in patients with respiratory dysfunction. RESPINOR DXT was twice ranked number one in the European Commission’s Horizon 2020 program, both in phase I and phase II, addressing an unmet medical need because every breath counts.

Currently, the company has initiated clinical observational studies in Europe (Norway, France, and Italy), which will lead to a multinational multicenter study for the first indication in mechanical ventilation (MV).

RESPINOR’s technology has a broad range of potential benefits and represents an enabling technology platform for application in critical care and other areas of respiratory medicine.

Mechanical ventilation (MV): Patients are placed on invasive MV because they are unable to sustain breathing on their own in such a way as to maintain sufficient gas exchange (oxygen uptake, carbon dioxide elimination). The most common underlying clinical conditions that are associated with acute respiratory failure and the subsequent need for MV include postoperative respiratory failure, neurologic disease, pneumonia, chronic obstructive pulmonary disorder (COPD), congestive heart failure, and sepsis.

However, MV is associated with a number of complications including muscle atrophy (shrinkage due to underuse) and muscle fiber damage related to increases in protein breakdown caused by unloading of the diaphragm as the ventilator assumes control of respiration, pneumonia, and lung injury due to excessive pressure or volume of air forced into the lungs by the ventilator. The process of diaphragm muscle fiber damage and atrophy has been shown to begin as soon as within 3-4 days of commencing MV.

As such, the intensive care clinician must balance the need for MV to maintain adequate gas exchange with getting the patient off the ventilator as soon as possible (a process known as “weaning”) so as to avoid diaphragm dysfunction.

 

First patient enrolled in RESPINOR’s weaning study at St.Olav’s hospital in Trondheim, Norway.

By | RESPINOR general news | No Comments

Study title: Continuous measurement of diaphragm excursion as a predictor of extubation failure

The primary objective of this study is to compare diaphragm excursion values obtained around a 30- minute spontaneous breathing trial (SBT) using RESPINOR DXT in patients who are successfully and unsuccessfully weaned.

We expect this study to gain new valuable knowledge about spontaneous diaphragm activity during weaning from mechanical ventilation support and show that our device will offer a valuable tool to identify the optimal time for weaning and disconnection from the ventilator.

This study is observational and is the first use of RESPINOR DXT within the intensive care population. Similar observational studies with different objectives are planned to commence in Paris, Angers, and Lyon in April 2019. The data will be used to provide clinical evidence to support the development of protocols for further studies that will define specific patient benefits.

RESPINOR AS: A Norwegian medical device company founded in 2015 based on IP, prototypes and clinical development at the University of Oslo and NeoRad AS. RESPINOR is developing an objective measure of breathing for critically ill patients within intensive care. RESPINOR DXT (Diaphragm Excursion Technology) is non-invasive, easy to use and provides precise, real-time continuous monitoring of the diaphragm function, our main breathing muscle. Monitoring the up-and-down movement of the liver, RESPINOR DXT measures diaphragm excursion using the liver as a proxy for the motion of the diaphragm. The monitoring of the diaphragm may provide useful information to guide clinical decision making in patients with respiratory dysfunction. RESPINOR DXT was twice ranked number one in the European Commission’s Horizon 2020 program, both in phase I and phase II, addressing an unmet medical need because every breath counts.

Currently, the company has initiated clinical observational studies in Europe (Norway, France, and Italy), which will lead to a multinational multicenter study for the first indication in mechanical ventilation (MV).

RESPINOR’s technology has a broad range of potential benefits and represents an enabling technology platform for application in critical care and other areas of respiratory medicine.

Mechanical ventilation (MV): Patients are placed on invasive MV because they are unable to sustain breathing on their own in such a way as to maintain sufficient gas exchange (oxygen uptake, carbon dioxide elimination). The most common underlying clinical conditions that are associated with acute respiratory failure and the subsequent need for MV include postoperative respiratory failure, neurologic disease, pneumonia, chronic obstructive pulmonary disorder (COPD), congestive heart failure, and sepsis.

However, MV is associated with a number of complications including muscle atrophy (shrinkage due to underuse) and muscle fiber damage related to increases in protein breakdown caused by unloading of the diaphragm as the ventilator assumes control of respiration, pneumonia, and lung injury due to excessive pressure or volume of air forced into the lungs by the ventilator. The process of diaphragm muscle fiber damage and atrophy has been shown to begin as soon as within 3-4 days of commencing MV.

As such, the intensive care clinician must balance the need for MV to maintain adequate gas exchange with getting the patient off the ventilator as soon as possible (a process known as “weaning”) so as to avoid diaphragm dysfunction.

 

Respinor Nasdaq

RESPINOR at EIC investor’s day at Nasdaq Stockholm

By | RESPINOR general news | No Comments

Respinor Nasdaq

RESPINOR is pitching at EIC investor day at Nasdaq Stockholm, Sweeden and got the opportunity to ring the bell together with 15 top EU SME companies.

RESPINOR meets with Nasdaq and top VCs in Stockholm

On 7 March, 15 companies backed by the European Innovation Council(EIC) pilot headed to Stockholm to learn more about the IPO process and pitch to top European investors. RESPINOR was one of the selected companies to pitch and learn more about going public.

The event was promoted by the EIC pilot business acceleration services together with Nasdaq First North, one of the leading exchanges for European SMEs looking to raise capital in the public markets. It gathered 15 SMEs funded under the EIC SME Instrument program working on deep tech and at an upscaling or growth stage.

RESPINOR had the opportunity to hear the experience from other entrepreneurs who had taken the IPO road on Nasdaq First North, get a deeper insight on what it means to operate in the public environment and pitch to top-tier European venture capitalists.

At the event, Adam Kostyál, Senior Vice President of Listing Services EMEA at Nasdaq, shared the evolution of Nasdaq First North, his views on the European tech sector and how that reflects on the number of companies going public: “What’s happening in Europe is very exciting. There’s a whole technology framework in terms of entrepreneurs, investors and overall technology development which allows for an impact on so many sectors and dimensions of growth. Many of these companies remain in private hands for a very long time. What we want to do is to make these companies understand that the exchange can be an alternative for them.”

RESPINOR are very happy to be selected for this event promoted by the EIC pilot. We had the opportunity to engage in one-to-one meetings with investors and further deepen the discussion on our business model, technology and financing needs. Hopefully, we will get some positive follow-ups that can help us scale-up our business.

By: Trude Tingvoll, CBO

RESPINOR part of Norwegian Business Delegation to Beijing, China

By | RESPINOR general news | No Comments

RESPINOR is proud to be part of the Norwegian Business Delegation together with the Norwegian Royal Family and Norwegian ministers together with Innovation Norway to Beijing, China, 15-17 October 2018.

RESPINOR gave a presentation in the parallel session: Norway China Cooperation on Health Technology Solutions on RESPINOR DXT-breakthrough non-invasive technology, changing respiratory health for critically ill patients within intensive care.

By: Trude Tingvoll, Chief Business Officer